H-25362: Effect of Botulinum Neurotoxin Type A Prostate Injections on Neurogenesis and Gene Profile Expression in Men With Localized Prostate Cancer and Lower Urinary Tract Symptoms/BPH (Protocol 05-09-30-03).

Trial Profile

H-25362: Effect of Botulinum Neurotoxin Type A Prostate Injections on Neurogenesis and Gene Profile Expression in Men With Localized Prostate Cancer and Lower Urinary Tract Symptoms/BPH (Protocol 05-09-30-03).

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 02 Sep 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 02 Jun 2015 Status changed from active,no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 18 Jun 2013 Lead trial centre and investigator amended as reported by ClinicalTrials.gov.
    • 18 Jun 2013 Actual initiation date changed from Apr 2011 to Mar 2011, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top